TRACON Pharmaceuticals Announces Acceptance of the Envafolimab (KN035) NDA by the NMPA in China for Priority Review

NEXT STORY
XBiotech Announces Cerebrovascular Medical Advisory Board & Development of New Stroke Therapy
PREV STORY
Predictive Oncology Announces $2.2 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Precision Therapeutics Signs Definitive Merger Agreement with Helomics Holding Corporation

MINNEAPOLIS, June 28, 2018 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ:AIPT) (“Precision” or “the ...

author_avatar
NASDAQ Market News

RedHill Biopharma Announces QIDP Fast-Track Designation Granted by FDA to RHB-104 for Nontuberculous Mycobacteria Infections

RHB-104 has been granted Qualified Infectious Disease Product (QIDP) designation by the U.S. FDA ...

author_avatar
NASDAQ Market News

Sanofi : Positive results in Phase 3 trial for Toujeo® in children and adolescents with type 1 diabetes

author_avatar
NASDAQ Market News